Enliven Therapeutics, Inc. (NASDAQ:ELVN) to post earnings of ($0.55) per share in Q3 2024, Lifesci Capital forecasts

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report ) – Lifesci Capital raised their Q3 2024 EPS estimates for shares of Enliven Therapeutics in a research note issued on Wednesday, August 14th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings of ($0.55) per share for the quarter, up from their prior estimate of ($0.56). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($2.26) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q4 2024 earnings at ($0.57) EPS, FY2024 earnings at ($2.08) EPS and FY2025 earnings at ($2.64) EPS.

ELVN has been the subject of several other reports. Robert W. Baird initiated coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird RW upgraded Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

View Enliven Therapeutics’ latest stock report

Enliven Therapeutics price performance

NASDAQ:ELVN opened at $23.71 on Friday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -12.28 and a beta of 1.10. Enliven Therapeutics has a one year low of $9.80 and a one year high of $27.67. The company has a fifty day moving average price of $22.90 and a 200 day moving average price of $20.10.

Enliven Therapeutics (NASDAQ:ELVN – Get Your Free Report ) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17.

Insiders place their bets

In other Enliven Therapeutics news, COO Anish Patel sold 17,475 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $25.07, for a total value of $438,098.25. Following the completion of the sale, the chief operating officer now owns 376,552 shares in the company, valued at approximately $9,440,158.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Enliven Therapeutics news, COO Anish Patel sold 17,475 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $25.07, for a total transaction of $438,098.25. Following the completion of the transaction, the chief operating officer now owns 376,552 shares of the company’s stock, valued at approximately $9,440,158.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Also, insider Joseph P. Lyssikatos sold 3,099 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total transaction of $85,408.44. Following the transaction, the insider now directly owns 1,089,936 shares of the company’s stock, valued at approximately $30,038,636.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,668 shares of company stock valued at $3,057,633. Corporate insiders own 29.20% of the company’s shares.

Institutional inputs and outputs

Institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its holdings in shares of Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares in the last quarter. AJOVista LLC bought a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $28,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after acquiring an additional 1,029 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Enliven Therapeutics in the second quarter valued at about $4,489,000. Finally, Rhumbline Advisers boosted its holdings in shares of Enliven Therapeutics by 29.9% in the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after acquiring an additional 11,420 shares in the last quarter. Institutional investors own 95.08% of the company’s shares.

About Enliven Therapeutics

(Get a free report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help cancer patients. The company’s product candidates include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Recommended articles

Get Enliven Therapeutics news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enliven Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.